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Abstract
[177Lu]Lu-DOTA-PSMA-617 for PRRT is subject to radiolysis and therefore loses receptor affinity. This will be detrimental for 
treatment efficacy. In this study optimal quencher(s) (combinations) are determined to maintain radiochemical purity with a down-
scaled model. Downscaled model in terms of activity, but at similar concentrations. DOTA-PSMA-617 was labeled with  [177Lu]
LuCl3 with different molar- and volume activities. Either methionine, ethanol or both showed superior effects on the stabilizing 
radiochemical purity of  [177Lu]Lu-DOTA-PSMA-617. As a consequence, radiochemical purity of  [177Lu]Lu-DOTA-PSMA-617 
could be maintained by the addition of methionine and/or ethanol and downscaled model was proven and complementary.
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Introduction
Prostate cancer is one of the leading causes of cancer related 
deaths in men. In addition, out of all new cancer diagnoses 
in men it is estimated that 1 out of 5 is prostate cancer [1]. 
In nuclear medicine, diagnosis of prostate cancer, and to 
some degree staging, is currently being done using a posi-
tron emitting radionuclide coupled to prostate specific mem-
brane antigen (PSMA) [2–4].
Treatment of prostate cancer could be performed with 
PSMA similarly to diagnosis and staging but instead of using 
a diagnostic radionuclide such as Gallium-68 a therapeutic 
radionuclide such as Lutetium-177 would be used [3, 5, 6]. 
Both diagnosis and treatment depend on successful targeting 
of the tumor. An important factor in targeted therapy is affin-
ity of the ligand for its binding site. As the ligand is subject 
to high level radiolysis the ligand is degraded and loses its 
affinity. Thus, successful targeting begins with reducing deg-
radation i.e. radiolysis and thus ensuring high radiochemical 
purity (RCP) of the ligand.
Radiolysis can be reduced by addition of quenchers such 
as gentisic acid, ascorbic acid, ethanol and various others, 
either separately or in specific combinations and concentra-
tions, during or after labeling as described by de Blois et al. 
[7] and others [8–14]. However, usefulness (ability to reduce 
radiolysis) of a quencher or combination of quenchers is 
specific to the ligand. Therefore, experiments have been con-
ducted to determine the optimal quencher or combination 
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unless stated differently. DOTA-PSMA-617 (MW: 1042 g/
mol) was purchased from ABX (Radeberg, Germany). In 
addition, reagent and hardware kits for synthesis of 177Lu-
peptides (for use in combination with the SCINTOMICS 
GRP® synthesizer) were also purchased from ABX. This 
reagent and hardware kit consist of a cassette for synthesis 
of 177Lu-peptides and vials containing: sodium ascorbate, 
sodium acetate—trihydrate, 0.04 M acetic acid solution 
and sodium chloride/diethylenetriaminepentaacetic acid 
(DTPA) solution. Apart from sodium ascorbate in the rea-
gent and hardware kit a separate solution was also made 
from dry material from Bufa BV (Uitgeest, The Nether-
lands). Gentisic acid was purchased from Tyco Health 
Care (Petten, The Netherlands) and l-methionine from 
Fluka Biochemika (Buchs, Switzerland). Lutetium-177 
 (LuMark® Lutetium-177 chloride) was purchased from 
IDB Holland, an AAA company (Baarle-Nassau, the 
Netherlands).
Quality control
Quality control (QC) consisted of determining radiochemi-
cal yield (RCY, incorporation) and RCP. RCY was deter-
mined using instant thin layer chromatography (ITLC), 
more specifically on silica gel (ITLC-SG). RCY of the 
samples of interest was determined with two different 
eluents. The eluents were 0.1 M sodium citrate (pH = 5) 
[15], and a mix of 1 M ammonium acetate and methanol 
1:1 (V/V) [16]. For each measurement of RCY two strips 
were prepared, each being 1 cm wide and 10 cm long. On 
each strip an aliquot (~ 1 µL) of the sample of interest was 
applied on circa 1 cm from the bottom of the strip, after 
which the strip was placed into the eluent. After the elu-
ent had been displaced to the top of the strip, the strip was 
cut into five parts of 2 cm each. Each piece was measured 
in a gamma counter separately and RCY was calculated.
RCP was determined at end of synthesis (EOS), and 
thereafter, using reversed phase high performance liquid 
chromatography (RP-HPLC). RCP results obtained at EOS 
were set to 95% for each separate labeling (condition). 
The offset between this set 95% RCP and the measured 
RCP was recorded for each separate labeling (condition). 
This offset was used to correct RCP values determined at 
other points in time than at EOS for each labeling condi-
tion. This ensured that a proper and accurate comparison 
between labeling conditions could be obtained and pre-
sented in figures. However, due to the mathematical opera-
tion applied only relative decrease in RCP is assessed. 
However, in patient administration the absolute i.e. raw 
or uncorrected RCP values are of importance. Therefore, 
the absolute RCP values are given in the text additional to 
presented figures.
Instrument and conditions
A Perkin Elmer W2487 gamma counter was used to count 
ITLC-SG samples and calculate RCY. RCP measurements 
were conducted with an instrument set-up that consisted of a 
Waters Alliance HPLC system (Etten-leur, the Netherlands) 
and radio measurement set-up. HPLC system is comprised 
of an e2690/5 separation module, 2487 dual absorbance UV/
VIS detector in combination with a Waters symmetry  C18 
column (5 µm, 4.6 mm × 250 mm) (Etten-Leur, The Neth-
erlands). Radio measurements were performed with an 1ʺ 
NaI(Tl) Scionix crystal (Bunnik, The Netherlands) con-
nected to a Canberra Osprey multichannel analyzer and sig-
nal amplifier (Zellik, Belgium). Signal connection between 
radio measurement set-up and HPLC was obtained via a 
Waters BUS Satellite Interface. Samples for analysis were 
diluted to a volumetric activity of 0.8–1.0 MBq per 100 µL 
and separated using 0.1% trifluoroacetic acid (TFA, eluents 
A) and methanol (Eluents B) in combination with the gradi-
ent profile shown in Table 1. UV absorption was measured 
at 278 nm.
Determination of effectiveness of quencher (combinations)
Effectiveness of quenchers, either individually or combined, 
was determined by labeling DOTA-PSMA-617 with  [177Lu]
Lu in presence of quenchers and determining the RCP at 
multiple time point. The reaction mixture, in this preclini-
cal method, for radiolabeling consisted of 80 MBq of 177Lu 
in 0.05 M HCl with 1.92 nmol of DOTA-PSMA-617 dis-
solved in Milli-Q water, sodium acetate as buffer (≤ 2 µL 
of 2.5  M) without or with quencher(s) of interest in a 
final volume of 140 µL [17]. Labelings were performed in 
1.5 mL Microtubes (Sarstedt, Reinbach, Germany) All tested 
quencher(s) or quencher combination(s) and corresponding 
final concentrations are shown in Table 2. Here, a distinc-
tion is made between single quenchers and combination 
of quenchers. In case of single quenchers, multiple (final) 
quencher concentrations have been tested. Radiolabeling 
was conducted by heating the reaction mixture at 80 °C for 
20 min. Subsequently, the reaction mixture was cooled down 
to room temperature. After cooling down 5 µL of 4 mM 
Table 1  Gradient profile of eluents A and B used for the analysis of 
 [177Lu]Lu-DOTA-PSMA-617 samples
Time (min) A (%) B (%) Flow (mL/min)
0 85 15 1.0
20 0 100 1.0
25 0 100 1.0
25.01 85 15 1.0
30 85 15 1.0
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DTPA was added to complex any unbound  [177Lu]Lu. QC 
was performed as described, and RCP of  [177Lu]Lu-DOTA-
PSMA-617 [15] was determined at multiple time points 
within 24 h i.e. 2 h, 4 h and 24 h.
Downscaling labeling conditions
A therapeutic dose of  [177Lu]Lu-DOTA-PSMA-617 for 
patient administration is set at 4 GBq/~ 0.1 mg (~ 96 nmol) 
[18, 19]. Handling such an amount in an experimental set-up 
is undesirable. Therefore, we investigated whether measure-
ments on RCP could be simulated with proportionally lower 
amounts of activity, precursor and volume while maintaining 
molar activity.
Here, labeling of DOTA-PSMA-617 was conducted 
according to protocol described by ABX with the addi-
tion of gentisic acid during labeling and ethanol after labe-
ling. This resulted in the following labeling procedure. 
4 mg of gentisic acid was dissolved in 0.5 mL of Milli-Q 
water. In this gentisic acid solution 0.1 mg (~ 96 nmol) of 
DOTA-PSMA-617 was dissolved. Subsequently, 6 mL of 
the 0.04 M acetic acid solution was used to dissolve 13 mg 
of sodium ascorbate and 31 mg of sodium acetate—tri-
hydrate. The two solutions were combined to have a total 
volume of 6.5 mL. This resulting solution is referred to as 
solution-I (third column, Table 3). To solution-I, 4 GBq 
of  [177Lu]LuCl3 was added. Labeling was then initiated by 
heating the vial at 80 °C for 20 min. Labeling was stopped 
by cooling down the reaction mixture to room temperature. 
After labeling a solution, referred to as solution-II (fourth 
column, Table 3), containing sodium chloride, DTPA and 
ethanol was added to the reaction vial. This solution was 
created by adding 1.2 mL of ethanol (≥ 99%) to the sodium 
chloride/DTPA solution (10 mL) delivered with the hard-
ware and reagents kit. As a consequence, each vial con-
tained 3.5 mM ascorbate, 1.6 mM gentisic acid and 7% 
ethanol (v/v) after finalization of labeling. Table 3 shows 
the tested conditions regarding activity, precursor and vol-
ume. Depending on the condition of interest a specific 
volume from solution I was taken, corresponding amounts 
of  [177Lu]Lu and volume of solution II was added. QC was 
performed as described. RCP was determined at multiple 
time points within 24 h i.e. 2 h, 4 h and 24 h.
Optimizing quencher combination
The molar activity differs for therapeutic labeling conditions 
in comparison to ‘preclinical’ labeling conditions. Due to 
this (radiation absorbed) dose in vial also differs for both 
labeling conditions. Consequently, quencher(s) that appeared 
promising in protecting the ligand from radiolysis in ‘pre-
clinical’ labeling condition experiments are possibly not 
suitable with clinical therapeutic labeling conditions. There-
fore, quenchers or quencher combinations that showed prom-
ise were also tested under therapeutic labeling conditions. 
Again, RCP is determined for  [177Lu]Lu-DOTA-PSMA-617, 
after labeling in presence of quencher(s), at multiple time 
points within 24 h. However, as opposed to therapeutic labe-
ling conditions of 4 GBq/0.1 mg (~ 96 nmol) in ~ 17.7 mL 
labeling is conducted here with downscaled therapeutic 
conditions i.e. 62.5 MBq/1.5 nmol in 0.276 mL. This is in 
accordance with the lowest activity and volumes shown in 
Table 3. The reaction mixture for radiolabeling consisted 
of 62.5 MBq of  [177Lu]Lu in 0.05 M HCl with 1.5 nmol of 
DOTA-PSMA dissolved in Milli-Q water, sodium acetate 
as buffer (≤ 2 µL of 2.5 M) without or with quencher(s) of 
interest in a final volume of ~ 100 µL. All tested quencher(s) 
or quencher combination(s) and corresponding final concen-
trations are shown in Table 2. Radiolabeling was conducted 
by heating the reaction mixture at 80 °C for 20 min. Sub-
sequently, the reaction mixture was cooled down to room 
temperature and 175 µL of a solution containing DTPA and 
ethanol was added. QC was performed as described and RCP 
was determined at multiple time points within 24 h.
Table 2  Used quencher or quencher combination and corresponding 
(final) concentrations
Quencher(s) Reference Final concentra-
tion in [mM] / % 
(v/v)
No quenchers A –
Sodium ascorbate B 3.5; 10.9
Ascorbic acid C 3.5; 10.9
Gentisic acid D 3.5; 10
Methionine E 3.5; 10
Ethanol F 10%
Methionine/ethanol E/F 3.5; 10%
Gentisic acid/ascorbic acid D/C 3.5; 3.5
Gentisic acid/ascorbic acid/ethanol D/C/F 3.5; 3.5; 10%
Table 3  Specific conditions used in downscaling experiment





4.0 96 6.5 11
2.0 48 3.3 5.6
1.0 24 1.6 2.8
0.50 12 0.81 1.4
0.25 6 0.41 0.70
0.13 3 0.20 0.35
0.06 1.5 0.10 0.17
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Results
Determination of effectiveness of quencher 
(combinations)
RCY and RCP were determined for  [177Lu]Lu-DOTA-
PSMA-617 labeled under ‘preclinical’ labeling conditions, 
in absence or presence of different quenchers or quencher 
combinations, at 0, 2 h, 4 h and 24 h (see Fig. 1). RCY for 
each labeling was ≥ 98%. Figure 1 shows that the ligand 
degrades rapidly when no quencher is added during or 
after labeling. Here a RCP of 19.4 ± 2.2% was found 
after 24 h. The addition of any quencher or combination 
of quencher reduces degradation in the ligand, and thus 
ensures high(er) RCP e.g. a combination of gentisic acid 
and ascorbic acid (3.5 mM final concentration for both) 
ensures a RCP of 73.8 ± 3.1% after 24 h. High RCP can be 
maintained using either 10% ethanol or 10 mM methionine 
which show RCPs of 90.3 ± 2.2% and 89.2 ± 2.0% after 
24 h, respectively.
Downscaling labeling conditions
RCY was determined directly after labeling. RCY for each 
labeling was ≥ 98%. RCP of  [177Lu]Lu-DOTA-PSMA-617 
was determined for therapeutic amounts (4 GBq/ 96 nmol 
in 17.7 mL) and various proportionally smaller activities, 
volumes and precursor at different points in time. At any 
point in time the range in RCP for the various labeling speci-
fications (activity, volume and precursor) is less than 1.2%, 
with a corresponding standard deviation of 0.4% (see Fig. 2). 
These results show that sufficiently accurate measurements 
on RCP of  [177Lu]Lu-DOTA-PSMA-617 can be performed 
with low amount of activity, volume and precursor e.g. 
0.063 GBq/0.28 mL/1.5 nmol while mimicking the effect 
of radiolysis on a therapeutic amount.
Optimized quencher combination
Results on RCP measurements with  [177Lu]Lu-DOTA-
PSMA-617 labeled under ‘preclinical’ conditions showed 
that two specific quenchers, at specific final concentration, 
Fig. 1  RCP  of[177Lu]Lu-DOTA-
PSMA-617, labeled under 
‘preclinical’ labeling conditions, 
in absence and presence of 
various quenchers and quencher 
combinations. As stated in 
Table 2: a no quencher added. 
b–e As described in Table 2 and 
f ethanol
Fig. 2  RCP of  [177Lu]
Lu-DOTA-PSMA-617 labeled 
under therapeutical labeling 
conditions and various propor-
tionally lower activities, vol-
umes and precursor at multiple 
time points
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were able to maintain RCP and therefore protect the ligand 
for degradation (radiolysis). Since labeling conditions are 
different for therapeutic amounts, albeit slightly, a number 
of quenchers and/or combination of quenchers were tested 
during labeling to determine their ability to reduce radioly-
sis during and after labeling. The results of these measure-
ment are shown in Fig. 3. Here it is shown that without the 
addition of any quencher the RCP of  [177Lu]Lu-DOTA-
PSMA-617 is decreased rapidly to 33.5 ± 3.9%. Best condi-
tions to maintain RCP are by either using 10% ethanol (v/v) 
or a combination of 3.5 mM methionine and 7% ethanol 
(v/v), for HPLC chromatogram see Fig. 4. RCPs found were 
96.2 ± 1.6% and 96.2 ± 0.8%, respectively.
Discussion
Patient administration of radiopharmaceuticals require, in 
most cases, a RCP of ≥ 95% at EOS. In figures presented 
here all shown labeling conditions start at 95% at EOS i.e. 
the limit of tolerable. The RCP at EOS was set to 95% to 
ensure proper comparison of measurement results. From fig-
ures relative change in RCP for quencher combinations can 
be determined, and as a consequence optimal labeling condi-
tions can be determined. However, showing relative change 
in RCP is not sufficient since patient administration of an 
radiopharmaceutical requires the RCP to be absolute and 
above a specific threshold. Therefore, RCP at EOS should 
Fig. 3  RCP of  [177Lu]
Lu-DOTA-PSMA-617, labeled 
with downscaled ‘therapeutic’ 
labeling conditions, in absence 
and presence of various quench-
ers
Fig. 4  [177Lu]Lu-PSMA-617 labeled under ideal quencher mixture (red line, condition E, Figs. 1, 3) and  [177Lu]Lu-PSMA-617 after 2 h (green 
line) and 24 h (blue line) without quenchers (condition A, Figs. 1, 3) added. This figure show the need and effectivity of quenchers added.
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always be shown in addition to relative measurements of 
RCP. Here, an absolute RCP of minimum 92.1 and a maxi-
mum of 98.9% (mean: 96.1 ± 2.0, n = 75) was measured at 
EOS.
Radiolysis in  [177Lu]Lu-DOTA-PSMA-617 has been 
shown to be reduced by the addition of specific chemicals 
i.e. quenchers such as methionine and ethanol. It is expected 
that there are a number of other chemicals that have identi-
cal or better capabilities for reducing radiolysis in  [177Lu]
Lu-DOTA-PSMA-617. The decision to use the chemicals as 
used here was the availability of GMP grade chemicals and 
the history of use in patients (intravenous administration). 
All chemicals are allowed to be used in patient and have also 
been used in patients already.
In addition to the limited number of chemicals tested, not 
all possible combinations and concentrations of the used 
chemicals have been tested. Tested combinations were based 
on results from past experiments with other radiolabeled 
ligands in which the used combinations and concentrations 
(e.g. gentisic acid/ascorbic acid and ethanol) showed that 
these reduce radiolysis for these ligands.
Successfully maintaining high RCP for  [177Lu]Lu-DOTA-
PSMA-617 can be obtained by using ethanol and/or methio-
nine. However, depending on the labeling conditions dif-
ferent concentrations are used for either single quenchers 
or combination of quenchers. This is due to a difference in 
absorbed dose in the vial. This has readily been shown by 
de Blois et al. [7] and is also confirmed here with samples to 
which no quencher has been added. Under therapeutical con-
ditions a higher RCP (~ 36%) is found when no quencher is 
used when comparing to the samples labeled under ‘preclini-
cal’ labeling conditions and no quencher is used (~ 26%). 
This is most likely due to the difference in volume used 
during and after labeling and a possible self-quenching effect 
(higher mass used under therapeutical conditions). Recently 
Chakraborty et al. [20] published about stability of  [177Lu]
Lu-DOTA-PSMA-617 as well. In this paper it is stated that 
stability can be maintained up to > 98% for 4 days. These 
results were not all in line with our findings. This could be 
very well related to the their different HPLC conditions [7], 
used equipment and interpretation of HPLC chromatograms 
[21].
Conclusion
Protecting  [177Lu]Lu-DOTA-PSMA-617 from a high level 
of radiolysis, and thus maintaining RCP, can be easily 
obtained by the addition of specific quencher combina-
tions. The choice of quencher or quencher combination to 
use depends on the labeling conditions i.e. molar activity. 
When labeling a product under ‘preclinical’ conditions i.e. 
80 MBq/1.9 nmol in 0.14 mL with 10 mM of methionine 
and 10% ethanol offer the best protection against radioly-
sis of all tested quenchers and quencher combinations. In 
case of labeling performed under ‘downscaled’ therapeu-
tical conditions i.e. 0.063 GBq/1.5 nmol in 0.28 mL with 
10% of ethanol or a combination of ethanol and methionine 
(7% and 3.5 mM respectively) offer the best protection to 
reduce radiolysis. The downscaled therapeutical labeling 
condition measurements have been proved to mimic thera-
peutical labeling conditions i.e. 4 GBq/0.1 mg (~ 96 nmol) 
in 17.7 mL. Therefore, it can be assumed that the quenchers, 
or combination of quenchers, that offer the best protection to 
reduce radiolysis will also do so with therapeutical labeling 
conditions.
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